HCV相关肾损伤及其治疗的研究进展

卢淑媛; 饶慧瑛

doi:10.3969/j.issn.1001-5256.2017.06.030

HCV相关肾损伤及其治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.06.030

北京大学人民医院北京大学肝病研究所

详细信息

中图分类号: R512.63;R692
计量
- 文章访问数: 2390
- HTML全文浏览量: 12
- PDF下载量: 462
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Research advances in hepatitis C virus-related renal injury and its treatment

摘要

摘要: HCV是一种血源性传播的病毒,是导致肝硬化、肝细胞癌的主要原因之一。大量的流行病学研究证实了HCV感染和肾脏疾病的关系。混合性冷球蛋白血症相关的膜性增生性的肾小球肾炎是最常见的HCV相关性肾脏疾病类型,主要临床表现是肾病或肾炎综合征、蛋白尿、血尿、肾小球滤过率降低等。HCV相关肾脏疾病治疗主要包括抗病毒治疗、B淋巴细胞清除的治疗、非特异的免疫抑制治疗。同时,随着新型抗病毒药物上市,使不能耐受传统方案人群看到了希望。综述了HCV相关肾损伤的流行病学、临床表现、发病机制及治疗等方面的研究进展。
- 肝炎病毒属 /
- 肾疾病 /
- 冷球蛋白血症 /
- 抗病毒药 /
- 综述
Abstract: Hepatitis C virus (HCV) is a blood-borne virus transmitted through contact with blood and blood products, and it is a major cause of liver cirrhosis and hepatocellular carcinoma. Many epidemiological studies have confirmed the association between HCV infection and renal disease. Membranoproliferative glomerulonephritis associated with mixed cryoglobulinemia is the most common type of HCV-related renal disease manifesting as nephropathy or nephritic syndrome, proteinuria, hematuria, and reduced glomerular filtration rate. The treatment of HCV-related renal disease includes antiviral therapy, B cell clearance, and non-specific immunosuppressive therapy. At the same time, the launch of new antiviral drugs has brought hope to the patients who cannot tolerate conventional regimens. This article reviews the research advances in epidemiology, clinical manifestations, pathogenesis, and treatment of HCV-related renal injury.
- hepacivirus /
- kidney diseases /
- cryoglobulinemia /
- antiviral agents /
- review

HTML全文

参考文献(42)

[1]WHO.Hepatitis C fact sheets[EB/OL].[2016-7].http://www.who.int/mediacentre/factsheets/fs164/en/

[2]CACOUB P, RENOU C, ROSENTHAL E, et al.Extrahepatic manifestations associated with hepatitis C virus infection.A prospective multicenter study of 321 patients.The GERMIVIC.Groupe d'Etude et de Rechercheen Medecine Interne et Maladies Infectieuses sur le Virus de I'Hepatite C[J].Medicine (Baltimore) , 2000, 79 (1) :47-56.

[3]CACOUB P, POYNARD T, GHILLANI P, et al.Extrahepatic manifestations of chronic hepatitis C.MULTIVIRC Group.Multidepartment Virus C[J].Arthritis Rheum, 1999, 42 (10) :2204-2212.

[4]GILL K, GHAZINIAN H, MANCH R, et al.Hepatitis C virus as a systemic disease:reaching beyond the liver[J].Hepatol Int, 2016, 10 (3) :415-423.

[5]SATAPATHY SK, LINGISETTY CS, WILLIAMS S, et al.Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection[J].Hepatol Int, 2012, 6 (1) :369-378.

[6]BUTT AA, WANG X, FRIED LF.HCV infection and the incidence of CKD[J].Am J Kidney Dis, 2011, 57 (3) :396-402.

[7]LI WC, LEE YY, CHEN IC, et al.Age and genderdifferences in the relationship between hepat C infection and all stages of chronic kidney disease[J].J Viral Hepat, 2014, 21 (10) :706-715.

[8]YOUNOSSI Z, PARK H, HENRY L, et al.Extrahepatic manifestations of hepatitis C:a meta-analysis of prevalence, quality of life, and economic burden[J].Gastroenterology, 2016, 150 (7) :1599-1608.

[9]EL-SERAG HB, HAMPEL H, YEH C, et al.Extrahepatic manifestations of hepatitis C among United States male veterans[J].Hepatology, 2002, 36 (6) :1439-1445.

[10]FABRIZI F, PLAISIER E, SAADOUN D, et al.Hepatitis C virus infection and kidney disease:a meta-analysis[J].Clin J Am Soc Nephrol, 2012, 7 (4) :549-557.

[11] CHENG ZJ, ZHOU BT, LIU XQ.Extrahepatic manifestations of chronic hepatitis C:a clinical analysis of 297 cases[C].The 2013Annual Conference on Liver Diseases and Infection in Beijing:49-53. (in Chinese) 程兆晶, 周宝桐, 刘晓清.慢性丙型肝炎肝外表现297例临床分析[C].北京地区肝病、感染学术年会.2013:49-53.

[12]FABRIZI F, MESSA P, MARTIN P.Novel evidence on hepatitis C virus-associated glomerular disease[J].Kidney Int, 2014, 86 (3) :466-469.

[13]BARSOUM RS.Hepatitis C virus:from entry to renal injury—facts and potentials[J].Nephrol Dial Transplant, 2007, 22 (7) :1840-1848.

[14]WORNLE M, SCHMID H, BANAS B, et al.Novel role of tolllike receptor 3 in hepatitis C-associated glomerulonephritis[J].Am J Pathol, 2006, 168 (2) :370-385.

[15]BANAS MC, BANAS B, HUDKINS KL, et al.TLR4 links podocytes with the innate immune system to mediate glomerular injury[J].J Am Soc Nephrol, 2008, 19 (4) :704-713.

[16]MORALES JM, MORALES E, ANDRS A, et al.Glomerulonephritis associated with hepatitis C virus infection[J].Curr Opin Nephrol Hypertens, 1999, 8 (2) :205-211.

[17]OZKOK A, YILDIZ A.Hepatitis C virus associated glomerulopathies[J].World J Gastroenterol, 2014, 20 (24) :7544-7554.

[18]D'AMICO G.Renal involvement in hepatitis C infection:cryoglobulinemic glomerulonephritis[J].Kidney Int, 1998, 54 (2) :650-671.

[19]FABRIII F, POZZI C, FARINA M, et al.Hepatitis C virus infection and acute or chronic glomerulonephritis:an epidemiological and clinical appraisal[J].Nephrol Dial Transplant, 1998, 13 (8) :1991-1997.

[20]TANG SC, LAI KN.Hepatitis C virus-associated glomerulonephritis[J].Contrib Nephrol, 2013, 181:194-206.

[21]DAVDA R, PETERSON J, WEINER R, et al.Membranous glomerulonephritis in association with hepatitis C virus infection[J].Am J Kidney Dis, 1993, 22 (3) :452-455.

[22]ROLLINO C, ROCCATELLO D, GIACHINO O, et al.Hepatitis C virus infection and membranous glomerulonephritis[J].Nephron, 1991, 59 (2) :319-320.

[23]JI F, LI Z, GE H, et al.Successful interferon-alpha treatment in a patient with Ig A nephropathy associated with hepatitis C virus infection[J].Intern Med, 2010, 49 (22) :2531-2532.

[24]JI FP, LI ZX, TIAN CY, et al.Ig A nephropathy associated with hepatitis C virus infection:a case report[J].Chin J Hepatol, 2010, 18 (9) :718-719. (in Chinese) 纪泛扑, 李政霄, 田长印, 等.丙型肝炎相关性Ig A肾病1例[J].中华肝脏病杂志, 2010, 18 (9) :718-719.

[25]ALTRAIF IH, ABDULLA AS, ALSEBAYEL MI, et al.Hepatitis C associated glomerulonephritis[J].Am J Nephrol, 1995, 15 (5) :407-410.

[26]SHAH HH, PATEL C.Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis[J].Ren Fail, 2013, 35 (8) :1182-1185.

[27]FOGO A, QURESHI N, HORN RG.Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy[J].Am J Kidney Dis, 1993, 22 (3) :367-377.

[28]MARKOWITZ GS, CHENG JT, COLVIN RB, et al.Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy[J].J Am Soc Nephrol, 1998, 9 (12) :2244-2252.

[29]CORONEOS E, TRUONG L, OLIVERO J.Fibrillary glomerulonephritis associated with hepatitis C viral infection[J].Am J Kidney Dis, 1997, 29 (1) :132-135.

[30]GUERRA G, NARAYAN G, RENNKE HG, et al.Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection[J].Clin Nephrol, 2003, 60 (5) :364-368.

[31]FABRIZI F, PLAISIER E, SAADOUN D, et al.Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease[J].Am J Kidney Dis, 2013, 61 (4) :623-637.

[32]Kidney Disease:Improving Global Outcomes (KDIGO) .KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J].Kidney Int Suppl, 2008, 73 (Suppl 109) :s1-s99.

[33]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.

[34]ZHANG Y, LENG XJ, SHEN JC, et al.An excerpt of APASL consensus statements and recommendation on treament of hepatitis C[J].J Clin Hepatol, 2016, 32 (7) :1245-1247. (in Chinese) 张莹, 冷雪君, 申姣春, 等.《2016年亚太肝病学会共识建议:丙型肝炎的治疗》摘译[J].临床肝胆病杂志, 2016, 32 (7) :1245-1247.

[35]OHTA S, YOKOYAMA H, WADA T, et al.Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy[J].Am J Kidney Dis, 1999, 33 (6) :1040-1048.

[36]FABRIZI F, MARTIN P, CACOUB P, et al.Treatment of hepatitis C-related kidney disease[J].Expert Opin Pharmacother, 2015, 16 (12) :1815-1827.

[37]SAADOUN D, THIBAULT V, SI AHMED SN, et al.Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis:VASCUVALDIC study[J].Ann Rheum Dis, 2016, 75 (10) :1777-1782.

[38]SISE ME, BLOOM AK, WISOCKY J, et al.Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents[J].Hepatology, 2016, 63 (2) :408-417.

[39]ROTH D, NELSON D, BRUCHFELD A, et al.LP02:C-surfer:grazoprevir plus elbasvir in treatment-na6ve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease[J].J Hepatol, 2015, 62:s263-s264.

[40]POCKROS PJ, REDDY KR, MANTRY PS, et al.Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J].Gastroenterology, 2016, 150 (7) :1590-1598.

[41]MAHALE P, KONTOYIANNIS DP, CHEMALY RF, et al.Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients[J].J Hepatol, 2012, 57 (6) :1177-1185.

[42]SAADOUN D, ROSENZWAJG M, JOLY F, et al.Regulatory Tcell responses to low-dose interleukin-2 in HCV-induced vasculitis[J].N Engl J Med, 2011, 365 (22) :2067-2077.

施引文献

资源附件(0)

访问统计